 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Review, Journal: Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. (Pubmed Central) - Mar 5, 2022
Additionally, dendritic cells (LV-SMENP-DC) and artificial antigen-presenting (aAPC) cells modified with lentiviral vector have also been developed to inhibit viral activity. Recombinant vaccines against COVID-19 are continuously being applied, and new clinical trials have been tested by interchangeability studies of viral vaccines developed by classical and next-generation platforms.
- | LV-DC vaccine / SZGIMI
New P1/2 trial: Immunity and Safety of Covid-19 Synthetic Minigene Vaccine (clinicaltrials.gov) - Feb 19, 2020
P1/2, N=100, Recruiting, Sponsor: Shenzhen Geno-Immune Medical Institute